Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OAETREATe: Ivermectin Frequency for Onchocerciasis-associated Epilepsy
NCT03852303Phase 4Completed
- Sponsor
- University of Antwerp
- Start
- Oct 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ivermectin in onchocerciasis-associated epilepsy (OAE) (3 arms), sponsored by University of Antwerp. Primary endpoint: Seizure Freedom. Started Oct 2017; status: completed.
02
Drugs
ivermectin
03
Conditions
onchocerciasis-associated epilepsy (OAE)
Beyond the preview
Go deeper on NCT03852303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03852303.